{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:37:29Z","timestamp":1783744649858,"version":"3.55.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":608,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1111\/bjd.12687","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T06:16:46Z","timestamp":1381731406000},"page":"20-30","source":"Crossref","is-referenced-by-count":59,"title":["Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review"],"prefix":"10.1093","volume":"170","author":[{"given":"Z.V.","family":"Fong","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Massachusetts General Hospital; Harvard Medical School; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.K.","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Massachusetts General Hospital; Harvard Medical School; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"10.1111\/bjd.12687-BIB0001|bjd12687-cit-0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/bjd.12687-BIB0002|bjd12687-cit-0002","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/11589300-000000000-00000","article-title":"Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature","volume":"29","author":"Guy","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"Suppl. 2","key":"10.1111\/bjd.12687-BIB0003|bjd12687-cit-0003","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/modpathol.3800517","article-title":"Prognosticators of melanoma, the melanoma report, and the sentinel lymph node","volume":"19","author":"Crowson","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1111\/bjd.12687-BIB0004|bjd12687-cit-0004","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0005|bjd12687-cit-0005","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0006|bjd12687-cit-0006","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1524-4725.2006.32101.x","article-title":"Role of sun exposure in melanoma","volume":"32","author":"Ivry","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.1111\/bjd.12687-BIB0007|bjd12687-cit-0007","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bjc.2012.22","article-title":"Skin cancer screening participation and impact on melanoma incidence in Germany - an observational study on incidence trends in regions with and without population-based screening","volume":"106","author":"Waldmann","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1111\/bjd.12687-BIB0008|bjd12687-cit-0008","unstructured":"National Ccomprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf"},{"issue":"Suppl. 5","key":"10.1111\/bjd.12687-BIB0009|bjd12687-cit-0009","doi-asserted-by":"crossref","first-page":"v194","DOI":"10.1093\/annonc\/mdq188","article-title":"Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Dummer","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1111\/bjd.12687-BIB0010|bjd12687-cit-0010","unstructured":"Australian Cancer Network and New Zealand Guidelines Group Clinical practice guidelines for the management of melanoma in Australia and New Zealand http:\/\/www.nhmrc.gov.au\/_files_nhmrc\/publications\/attachments\/cp111.pdf"},{"key":"10.1111\/bjd.12687-BIB0011|bjd12687-cit-0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaad.2005.08.072","article-title":"Clinical outcomes from skin screening clinics within a community-based melanoma screening program","volume":"54","author":"Aitken","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12687-BIB0012|bjd12687-cit-0012","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/aje\/kwj204","article-title":"Validity of melanoma diagnosis in a community-based screening program","volume":"164","author":"Fritschi","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1111\/bjd.12687-BIB0013|bjd12687-cit-0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jms.5.3.156","article-title":"General practitioner screening for melanoma: sensitivity, specificity, and effect of training","volume":"5","author":"Burton","year":"1998","journal-title":"J Med Screen"},{"key":"10.1111\/bjd.12687-BIB0014|bjd12687-cit-0014","unstructured":"Cancer Care Ontario Screening for skin cancer https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?serverId=6&path=\/File%20Database\/CCO%20Files\/PEBC\/pebc15-1s.pdf"},{"key":"10.1111\/bjd.12687-BIB0015|bjd12687-cit-0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/canjclin.56.1.11","article-title":"American Cancer Society guidelines for the early detection of cancer, 2006","volume":"56","author":"Smith","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/bjd.12687-BIB0016|bjd12687-cit-0016","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3322\/canjclin.41.4.201","article-title":"Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin","volume":"41","author":"Friedman","year":"1991","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/bjd.12687-BIB0017|bjd12687-cit-0017","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cncr.10880","article-title":"Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics","volume":"95","author":"Schwartz","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0018|bjd12687-cit-0018","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archderm.139.3.289","article-title":"Analysis of heterogeneity of atypia within melanocytic nevi","volume":"139","author":"Barr","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12687-BIB0019|bjd12687-cit-0019","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.amjsurg.2005.08.020","article-title":"Is incisional biopsy of melanoma harmful?","volume":"190","author":"Martin","year":"2005","journal-title":"Am J Surg"},{"key":"10.1111\/bjd.12687-BIB0020|bjd12687-cit-0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1067\/mjd.2002.123488","article-title":"Incisional biopsy and melanoma prognosis","volume":"46","author":"Bong","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12687-BIB0021|bjd12687-cit-0021","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM198805053181804","article-title":"Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm","volume":"318","author":"Veronesi","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0022|bjd12687-cit-0022","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D","article-title":"Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0\u00b78-2\u00b70 mm","volume":"89","author":"Cohn-Cedermark","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0023|bjd12687-cit-0023","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/cncr.11272","article-title":"Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2\u00b71-mm thick)","volume":"97","author":"Khayat","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0024|bjd12687-cit-0024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa030681","article-title":"Excision margins in high-risk malignant melanoma","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0025|bjd12687-cit-0025","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial","volume":"378","author":"Gillgren","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/bjd.12687-BIB0026|bjd12687-cit-0026","first-page":"419","article-title":"Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis","volume":"46","author":"Haigh","year":"2003","journal-title":"Can J Surg"},{"key":"10.1111\/bjd.12687-BIB0027|bjd12687-cit-0027","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(05)70423-X","article-title":"Lymphatic mapping in management of patients with primary cutaneous melanoma","volume":"6","author":"Thompson","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1111\/bjd.12687-BIB0028|bjd12687-cit-0028","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","article-title":"Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma","volume":"16","author":"Gershenwald","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0029|bjd12687-cit-0029","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0030|bjd12687-cit-0030","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","article-title":"The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I)","volume":"17","author":"Faries","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0031|bjd12687-cit-0031","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0032|bjd12687-cit-0032","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ncponc1205","article-title":"The rationale for sentinel-node biopsy in primary melanoma","volume":"5","author":"Morton","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1111\/bjd.12687-BIB0033|bjd12687-cit-0033","doi-asserted-by":"crossref","first-page":"308","DOI":"10.6004\/jnccn.2009.0023","article-title":"Role of sentinel lymph node biopsy in patients with thin melanoma","volume":"7","author":"Andtbacka","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/bjd.12687-BIB0034|bjd12687-cit-0034","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/BF02574479","article-title":"Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status","volume":"9","author":"Ferrone","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0035|bjd12687-cit-0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10434-000-0160-4","article-title":"Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (\u2265 4 mm) primary melanoma","volume":"7","author":"Gershenwald","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0036|bjd12687-cit-0036","unstructured":"Cancer Care Ontario Primary excision margins and sentinel lymph node biopsy in clinically node-negative cutaneous melanoma of the trunk or extremities https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?fileId=73874"},{"key":"10.1111\/bjd.12687-BIB0037|bjd12687-cit-0037","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1\u00b75 mm without clinically detectable node metastases. French Cooperative Group on Melanoma","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/bjd.12687-BIB0038|bjd12687-cit-0038","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group","volume":"16","author":"Pehamberger","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0039|bjd12687-cit-0039","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(01)06068-8","article-title":"Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial","volume":"358","author":"Cascinelli","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/bjd.12687-BIB0040|bjd12687-cit-0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/bjd.12687-BIB0041|bjd12687-cit-0041","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0042|bjd12687-cit-0042","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0043|bjd12687-cit-0043","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.12687-BIB0044|bjd12687-cit-0044","unstructured":"Cancer Care Ontario Systemic adjuvant therapy for patients at high risk for recurrent melanoma https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?serverId=6&path=\/File%20Database\/CCO%20Files\/PEBC\/pebc8-1s.pdf"},{"key":"10.1111\/bjd.12687-BIB0045|bjd12687-cit-0045","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1002\/cncr.24627","article-title":"The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma","volume":"115","author":"Agrawal","year":"2009","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0046|bjd12687-cit-0046","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","article-title":"Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial","volume":"13","author":"Burmeister","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1111\/bjd.12687-BIB0047|bjd12687-cit-0047","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<88::AID-CNCR13>3.0.CO;2-K","article-title":"Locally advanced melanoma: results of postoperative hypofractionated radiation therapy","volume":"88","author":"Stevens","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0048|bjd12687-cit-0048","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.radonc.2006.10.001","article-title":"A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma - Trans Tasman Radiation Oncology Group (TROG) Study 96\u00b706","volume":"81","author":"Burmeister","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1111\/bjd.12687-BIB0049|bjd12687-cit-0049","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/1097-0142(19950115)75:2<478::AID-CNCR2820750211>3.0.CO;2-O","article-title":"Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases","volume":"75","author":"Carlson","year":"1995","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0050|bjd12687-cit-0050","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1200\/JCO.2005.04.515","article-title":"Biology of desmoplastic melanoma: a case-control comparison with other melanomas","volume":"23","author":"Livestro","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0051|bjd12687-cit-0051","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/cncr.23895","article-title":"Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases","volume":"113","author":"Chen","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0052|bjd12687-cit-0052","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00000658-198307000-00013","article-title":"Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma","volume":"198","author":"Roses","year":"1983","journal-title":"Ann Surg"},{"key":"10.1111\/bjd.12687-BIB0053|bjd12687-cit-0053","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0054|bjd12687-cit-0054","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1524-4725.1993.tb00989.x","article-title":"Pooled analysis of the efficacy of bacille Calmette-Gu\u00e9rin (BCG) immunotherapy in malignant melanoma","volume":"19","author":"Tan","year":"1993","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0055|bjd12687-cit-0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/bjs.1800830425","article-title":"Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma","volume":"83","author":"Hill","year":"1996","journal-title":"Br J Surg"},{"key":"10.1111\/bjd.12687-BIB0056|bjd12687-cit-0056","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1524-4725.2004.30091.x","article-title":"Locoregional cutaneous metastases of malignant melanoma and their management","volume":"30","author":"Wolf","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1111\/bjd.12687-BIB0057|bjd12687-cit-0057","first-page":"555","article-title":"Topical imiquimod treatment of a cutaneous melanoma metastasis","volume":"43","author":"Steinmann","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12687-BIB0058|bjd12687-cit-0058","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1470-2045(03)01117-3","article-title":"Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials","volume":"4","author":"Lens","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1111\/bjd.12687-BIB0059|bjd12687-cit-0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jso.20112","article-title":"Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion","volume":"88","author":"Thompson","year":"2004","journal-title":"J Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0060|bjd12687-cit-0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/02656730903236086","article-title":"Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities","volume":"26","author":"Boesch","year":"2010","journal-title":"Int J Hyperthermia"},{"key":"10.1111\/bjd.12687-BIB0061|bjd12687-cit-0061","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","article-title":"A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US","volume":"208","author":"Beasley","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1111\/bjd.12687-BIB0062|bjd12687-cit-0062","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1997.15.3.1039","article-title":"Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system","volume":"15","author":"Buzaid","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0063|bjd12687-cit-0063","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0064|bjd12687-cit-0064","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0065|bjd12687-cit-0065","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0066|bjd12687-cit-0066","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12687-BIB0067|bjd12687-cit-0067","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"10.1111\/bjd.12687-BIB0068|bjd12687-cit-0068","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","article-title":"Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience","volume":"44","author":"Seegenschmiedt","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/bjd.12687-BIB0069|bjd12687-cit-0069","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.22988","article-title":"A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma","volume":"110","author":"Olivier","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/bjd.12687-BIB0070|bjd12687-cit-0070","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","article-title":"Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines","volume":"28","author":"Romano","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12687-BIB0071|bjd12687-cit-0071","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1470-2045(05)70283-7","article-title":"Follow-up in patients with localised primary cutaneous melanoma","volume":"6","author":"Francken","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1111\/bjd.12687-BIB0072|bjd12687-cit-0072","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.294.13.1647","article-title":"Clinicopathological features of and risk factors for multiple primary melanomas","volume":"294","author":"Ferrone","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/bjd.12687-BIB0073|bjd12687-cit-0073","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2133.1999.02657.x","article-title":"A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group","volume":"140","author":"Dicker","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12687-BIB0074|bjd12687-cit-0074","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1245\/s10434-007-9347-2","article-title":"Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines","volume":"14","author":"Francken","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/bjd.12687-BIB0075|bjd12687-cit-0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2133.2004.06262.x","article-title":"Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients","volume":"152","author":"Machet","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12687-BIB0076|bjd12687-cit-0076","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"10.1111\/bjd.12687-BIB0077|bjd12687-cit-0077","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1111\/bjd.12687-BIB0078|bjd12687-cit-0078","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/PPO.0b013e31827654ea","article-title":"Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive","volume":"18","author":"Fong","year":"2012","journal-title":"Cancer J"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12687","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12687\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:07:23Z","timestamp":1676383643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/170\/1\/20\/6615061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12687","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}